Jaguar Health (JAGX) FCF Margin (2015 - 2026)
Jaguar Health (JAGX) posted quarterly FCF Margin of 43.74% for Q1 2026, up 37409.0% year-over-year from N/an in Q1 2025, and up 133.21% quarter-over-quarter from 131.72% in Q4 2025.
Jaguar Health (JAGX) FCF Margin (2015 - 2026) Analysis & Trends
Jaguar Health (JAGX) has reported FCF Margin for 12 consecutive years, with 43.74% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 37409.0% year-over-year to 43.74%; the TTM figure through Mar 2026 stood at 21.77% (up 24140.0% YoY), while the FY2025 annual figure was 195.58%, up 5594.0% from the prior year.
- FCF Margin climbed to 43.74% in Q1 2026 per JAGX's latest filing, from 131.72% in the prior quarter.
- Across five years, FCF Margin topped out at 43.74% in Q1 2026 and bottomed at 38500.0% in Q1 2022.
- Historically, FCF Margin has averaged 4705.21% across 5 years, with a median of 278.97% in 2022.
- Annual changes were most pronounced in 2022 — FCF Margin slumped 3794619 bps — and 2024, when it soared 2187152 bps.
- Jaguar Health's FCF Margin stood at 15953.12% in 2022, then surged by 98 bps to 323.83% in 2023, then surged by 34 bps to 214.05% in 2024, then surged by 38 bps to 131.72% in 2025, then soared by 133 bps to 43.74% in 2026.
- Business Quant data shows JAGX's FCF Margin at 43.74% in Q1 2026, 131.72% in Q4 2025, and 157.28% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.69 Bn | 130.84 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.29 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.79 Bn | 59.60 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.44 Bn | 54.31 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.92 Bn | 27.61 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.10 Bn | 9.71 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.33 Bn | 26.17 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 70.82% |
| 10 | Jaguar Health | 459,102.90 | -9.60 Mn | 19.11 Mn | 43.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.74% |
| Dec 31, 2025 | -131.72% |
| Sep 30, 2025 | -157.28% |
| Jun 30, 2025 | -207.96% |
| Mar 31, 2025 | -330.35% |
| Dec 31, 2024 | -214.05% |
| Sep 30, 2024 | -214.16% |
| Jun 30, 2024 | -327.86% |
| Mar 31, 2024 | -268.48% |
| Dec 31, 2023 | -323.83% |
| Sep 30, 2023 | -241.52% |
| Jun 30, 2023 | -344.65% |
| Mar 31, 2023 | -22,140.00% |
| Dec 31, 2022 | -15,953.13% |
| Sep 30, 2022 | -278.97% |
| Jun 30, 2022 | -398.36% |
| Mar 31, 2022 | -38,500.00% |
| Dec 31, 2021 | -431.06% |
| Sep 30, 2021 | -1,533.66% |
| Jun 30, 2021 | -2,608.97% |